Genmab — Maj 2018
-
Hermed kommentar fra Bowers: MM spill over. We do not see any material negative spill over to the Multiple Myeloma (MM) indications from which we still project more than USD9bn in peak sales. However, the increased mortality-related events in the study does, in our view, make Darzalex as a back-bone MM therapy potentially more vulnerable as the PD-1/PD-L1 combination option right now is gone - at least until the possible safety issues with the combination have been fully elucidated. We see PoC
-
-
Genmab gør hvad de skal. Længere er den ikke.
-
Alt bull er vel lukket ned nu?
-
Enig Gentogen.
-
@Helge: Taler reaktionen på markdet ikke for sig selv - de skal naturligvis ikke kommenteres direkte på kursen. Men når markedet vurderer selskabet bliver 20 mia mindre værd...så må de et eller andet sted være have en interesse i at komme med en kommentar
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind